Department of Infectious Diseases, Renmin Hospital of Wuhan University, No. 99 Zhangzhidong Road, Wuchang District, Hubei, China.
Wuhan Optics Valley Vcanbiopharma Co., Ltd., Hubei, China.
Stem Cell Res Ther. 2023 Sep 23;14(1):267. doi: 10.1186/s13287-023-03494-2.
Recent studies have shown that mesenchymal stem cell (MSC) therapy has potential therapeutic effects for patients with end-stage liver diseases. However, a consensus on the efficacy and safety of MSCs has not been reached.
A systemic literature review was conducted by searching the Cochrane Library and PubMed databases for articles that evaluated the impact of MSC therapy on the outcomes among patients with end-stage liver disease. Various parameters, including pre- and post-treatment model of end-stage liver disease (MELD) score, serum albumin (ALB), total bilirubin (TB), coagulation function, aminotransferase, and survival rate, were evaluated.
This meta-analysis included a final total of 13 studies and 854 patients. The results indicated improved liver parameters following MSC therapy at different time points, including in terms of MELD score, TB level, and ALB level, compared with conventional treatment. Furthermore, the MSC treatment increased the overall survival rate among patients with liver cirrhosis and acute-on-chronic liver failure (ACLF). The changes in transaminase level and coagulation function differed between the different therapies at various post-treatment time points, indicating that MSC therapy provided no significant benefits in this regard. The further subgroup analysis stratified by liver background revealed that patients with ACLF benefit more from MSC therapy at most time points with improved liver function, including in terms of MELD score, TB level, and ALB level. In addition, no serious side effects or adverse events were reported following MSC therapy.
The meta-analysis results suggest that MSC therapy is safe and results in improved liver function and survival rates among patients with end-stage liver disease. The subgroup analysis stratified by liver background indicated that patients with ACLF benefit more from MSC therapy than patients with liver cirrhosis at most time points.
最近的研究表明，间充质干细胞（MSC）治疗对终末期肝病患者具有潜在的治疗效果。然而，对于 MSC 的疗效和安全性尚未达成共识。
通过检索 Cochrane 图书馆和 PubMed 数据库，对评估 MSC 治疗对终末期肝病患者结局影响的文章进行了系统的文献回顾。评估了各种参数，包括治疗前后终末期肝病模型（MELD）评分、血清白蛋白（ALB）、总胆红素（TB）、凝血功能、转氨酶和生存率。
这项荟萃分析共纳入了 13 项研究和 854 名患者。结果表明，与常规治疗相比，MSC 治疗在不同时间点改善了肝脏参数，包括 MELD 评分、TB 水平和 ALB 水平。此外，MSC 治疗增加了肝硬化和慢加急性肝衰竭（ACLF）患者的总生存率。不同治疗后不同时间点的转氨酶和凝血功能变化表明，MSC 治疗在这方面没有显著益处。按肝背景进行的进一步亚组分析表明，在大多数时间点，ACLF 患者从 MSC 治疗中获益更多，肝功能得到改善，包括 MELD 评分、TB 水平和 ALB 水平。此外，MSC 治疗后未报告严重的副作用或不良事件。
荟萃分析结果表明，MSC 治疗安全，并可改善终末期肝病患者的肝功能和生存率。按肝背景进行的亚组分析表明，在大多数时间点，ACLF 患者比肝硬化患者从 MSC 治疗中获益更多。
